longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Panlong Pharmaceutical

002864

20.592.42% ( -0.51 )
Delay Trading: Sep 11, 14:28:54
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 36.73, above the reasonable range, cheaper than 15.59% of the time in the past 5 years, and the industry ranks 87/221, the industry Median 23.68.

36.73xP/E
¥21.10Stock price
¥0.57Earnings per share
36.73xP/E
Stock price¥21.10Earnings per share¥0.57

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
29.80x
Typical range
24.96x–35.57x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 23.68x
010203040

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 23.68x
0x40x80x120x160x200x
P/E ratio
Name/Symbol
600276SHHengrui Pharma
36.88x17.99%¥284.93B
600436SHZZPZH
39.70x1.29%¥71.83B
002422SZKELUN PHARMA
34.91x15.33%¥63.85B
600085SHTRT
33.51x4.81%¥32.50B
600329SHDRTG
31.79x51.62%¥26.96B
000739SZAPELOA
30.16x23.79%¥25.64B
600521SHHuahaipharm
37.06x305.56%¥23.27B
002262SZNHWA
20.17x14.76%¥22.13B
600664SHHPGC
35.06x71.43%¥17.96B
603456SHJiuzhou Pharma
22.24x12.93%¥13.16B
603707SHNKF
25.40x22.22%¥12.26B
002019SZYifan Pharmaceutical
37.93x12.12%¥11.51B
600420SHSHYNDEC
20.81x--¥11.35B
600572SHCONBA
22.00x--¥10.97B
300357SZWolwo Pharma
24.37x18.88%¥10.17B
002626SZKingdomway
38.32x56.36%¥10.06B
688076SHSinopep
38.39x91.51%¥9.11B
002332SZXJZY
22.38x5.56%¥8.64B
002550SZQianhong Bio-pharma
28.77x--¥8.45B
300119SZRINGPU
23.79x4.75%¥8.28B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.